Incorporating Real Option Value in Valuing Innovation: A Way Forward
PharmacoEconomics · 2024-07 · 42 (S2) · 199-210
DOI: 10.1007/s40273-024-01352-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift PharmacoEconomics, online erschienen am 04.02.2024. Verfasst von Meng Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washingto…. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Models, Economic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA. Meng.li@tuftsmedicalcenter.org.
- The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.
ORCID-Profile: Meng Li
Zitieren
APA
Li, M., & Garrison, L. P. (2024). Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics, 42(S2), 199-210. https://doi.org/10.1007/s40273-024-01352-4
Vancouver
Li M, Garrison LP. Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics. 2024;42(S2):199-210. doi:10.1007/s40273-024-01352-4
BibTeX
@article{Li2024,
author = {Li, Meng and Garrison, Louis P},
title = {Incorporating Real Option Value in Valuing Innovation: A Way Forward},
journal = {PharmacoEconomics},
year = {2024},
volume = {42},
number = {S2},
pages = {199--210},
doi = {10.1007/s40273-024-01352-4}
}
EUVIMED